Diagnostic work-up in steroid myopathy
- 235 Downloads
Steroid myopathy is a well-known sign of endogenous Cushing’s syndrome as well as a side effect of glucocorticoid administration. The clinical finding of muscle weakness and the clinical inspection of the muscle size are the most commonly used diagnostic tools, sometimes in combination with needle electromyography, but there are no means to detect the myopathy before the appearance of clinical or electrodiagnostic signs. Until now, no guidelines have been produced for a disease-specific evaluation of muscle impairment in patients with Cushing’s syndrome.
We reviewed the measurement properties and limitations of the following tools that are currently adopted in clinical research and routine care for diagnosis and monitoring of steroid myopathy: muscle strength assessment; needle biopsy; intramuscular and surface electromyography; laboratory assays; muscle mass assessments (through bioelectrical impedance analysis, dual-energy X-ray absorptiometry, and computed tomography).
We suggest that the management of steroid myopathy patients in clinical research and practice would benefit from a multidisciplinary approach based on the combined assessment of muscle mass, strength, and performance. However, further studies are required to establish an operational definition of steroid myopathy and to identify population-specific criteria for diagnosis of the myopathic process.
KeywordsGlucocorticoids Steroid myopathy Sarcopenia Muscle weakness Muscle atrophy
Compliance with ethical standards
Conflict of interest
The authors declare that they have no competing interests.
- 14.D. Dumitru. Myopathies. in Electrodiagnostic Medicine, ed. by D. Dumitru (Hanley & Belfus: Philadelphia, 1995), pp. 1031–1129Google Scholar
- 16.M.A. Weber, H. Krakowski-Roosen, L. Schröder, R. Kinscherf, M. Krix, A. Kopp-Schneider, M. Essig, P. Bachert, H.U. Kauczor, W. Hildebrandt, Morphology, metabolism, microcirculation, and strength of skeletal muscles in cancer-related cachexia. Acta Oncol. 48, 116–124 (2009)CrossRefPubMedGoogle Scholar
- 22.M.A. Minetto, F. Lanfranco, A. Botter, G. Motta, G. Mengozzi, R. Giordano, A. Picu, E. Ghigo, E. Arvat, Do muscle fiber conduction slowing and decreased levels of circulating muscle proteins represent sensitive markers of steroid myopathy? A pilot study in Cushing’s disease. Eur. J. Endocrinol. 164, 985–993 (2011)CrossRefPubMedGoogle Scholar
- 25.N. Aranibar, J.D. Vassallo, J. Rathmacher, S. Stryker, Y. Zhang, J. Dai, E.B. Janovitz, D. Robertson, M. Reily, L. Lowe-Krentz, L. Lehman-McKeeman, Identification of 1- and 3-methylhistidine as biomarkers of skeletal muscle toxicity by nuclear magnetic resonance-based metabolic profiling. Anal. Biochem. 410, 84–91 (2011)CrossRefPubMedGoogle Scholar
- 27.D.L. Kendler, J.L. Borges, R.A. Fielding, A. Itabashi, D. Krueger, K. Mulligan, B.M. Camargos, B. Sabowitz, C.H. Wu, E.W. Yu, J. Shepherd, The official positions of the international society for clinical densitometry: Indications of use and reporting of DXA for body composition. J. Clin. Densitom. 16, 496–507 (2013)CrossRefPubMedGoogle Scholar
- 33.P.M. Cawthon, K.W. Peters, M.D. Shardell, R.R. McLean, T.T. Dam, A.M. Kenny, M.S. Fragala, T.B. Harris, D.P. Kiel, J.M. Guralnik, L. Ferrucci, S.B. Kritchevsky, M.T. Vassileva, S.A. Studenski, D.E. Alley, Cutpoints for low appendicular lean mass that identify older adults with clinically significant weakness. J. Gerontol. A. Biol. Sci. Med. Sci. 69, 567–575 (2014)CrossRefPubMedPubMedCentralGoogle Scholar
- 40.B.S. Miller, K.M. Ignatoski, S. Daignault, C. Lindland, P.G. Gauger, G.M. Doherty, S.C. Wang; University of Michigan Analytical Morphomics Group, A quantitative tool to assess degree of sarcopenia objectively in patients with hypercortisolism. Surgery 150, 1178–1185 (2011)CrossRefPubMedGoogle Scholar
- 47.R.A. Atkinson, U. Srinivas-Shankar, S.A. Roberts, M.J. Connolly, J.E. Adams, J.A. Oldham, F.C. Wu, O.R. Seynnes, C.E. Stewart, C.N. Maganaris, M.V. Narici, Effects of testosterone on skeletal muscle architecture in intermediate-frail and frail elderly men. J. Gerontol. A. Biol. Sci. Med. Sci. 65, 1215–1219 (2010)CrossRefPubMedGoogle Scholar
- 49.A.J. Cruz-Jentoft, J.P. Baeyens, J.M. Bauer, Y. Boirie, T. Cederholm, F. Landi, F.C. Martin, J.P. Michel, Y. Rolland, S.M. Schneider, E. Topinková, M. Vandewoude, M. Zamboni, European Working Group on Sarcopenia in Older People, Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in older people. Age Ageing 39, 412–423 (2010)CrossRefPubMedPubMedCentralGoogle Scholar
- 50.S.A. Studenski, K.W. Peters, D.E. Alley, P.M. Cawthon, R.R. McLean, T.B. Harris, L. Ferrucci, J.M. Guralnik, M.S. Fragala, A.M. Kenny, D.P. Kiel, S.B. Kritchevsky, M.D. Shardell, T.T. Dam, M.T. Vassileva, The FNIH sarcopenia project: rationale, study description, recommendations, and final estimates. J. Gerontol. A. Biol. Sci. Med. Sci. 69, 547–558 (2014)CrossRefPubMedPubMedCentralGoogle Scholar